Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
dc.creator | Berlow, Noah E. (TTU) | |
dc.creator | Rikhi, Rishi | |
dc.creator | Geltzeiler, Mathew | |
dc.creator | Abraham, Jinu | |
dc.creator | Svalina, Matthew N. | |
dc.creator | Davis, Lara E. | |
dc.creator | Wise, Erin | |
dc.creator | Mancini, Maria | |
dc.creator | Noujaim, Jonathan | |
dc.creator | Mansoor, Atiya | |
dc.creator | Quist, Michael J. | |
dc.creator | Matlock, Kevin L. (TTU) | |
dc.creator | Goros, Martin W. | |
dc.creator | Hernandez, Brian S. | |
dc.creator | Doung, Yee C. | |
dc.creator | Thway, Khin | |
dc.creator | Tsukahara, Tomohide | |
dc.creator | Nishio, Jun | |
dc.creator | Huang, Elaine T. | |
dc.creator | Airhart, Susan | |
dc.creator | Bult, Carol J. | |
dc.creator | Gandour-Edwards, Regina | |
dc.creator | Maki, Robert G. | |
dc.creator | Jones, Robin L. | |
dc.creator | Michalek, Joel E. | |
dc.creator | Milovancev, Milan | |
dc.creator | Ghosh, Souparno (TTU) | |
dc.creator | Pal, Ranadip (TTU) | |
dc.creator | Keller, Charles | |
dc.date.accessioned | 2023-07-14T17:17:50Z | |
dc.date.available | 2023-07-14T17:17:50Z | |
dc.date.issued | 2019 | |
dc.description | © 2019 The Author(s). cc-by | |
dc.description.abstract | Background: Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when their disease inevitably progresses. To address the unmet clinical need for evidence-based therapy assignment when standard clinical approaches have failed, we have developed a probabilistic computational modeling approach which integrates molecular sequencing data with functional assay data to develop patient-specific combination cancer treatments. Methods: Tissue taken from a murine model of alveolar rhabdomyosarcoma was used to perform single agent drug screening and DNA/RNA sequencing experiments; results integrated via our computational modeling approach identified a synergistic personalized two-drug combination. Cells derived from the primary murine tumor were allografted into mouse models and used to validate the personalized two-drug combination. Computational modeling of single agent drug screening and RNA sequencing of multiple heterogenous sites from a single patient's epithelioid sarcoma identified a personalized two-drug combination effective across all tumor regions. The heterogeneity-consensus combination was validated in a xenograft model derived from the patient's primary tumor. Cell cultures derived from human and canine undifferentiated pleomorphic sarcoma were assayed by drug screen; computational modeling identified a resistance-abrogating two-drug combination common to both cell cultures. This combination was validated in vitro via a cell regrowth assay. Results: Our computational modeling approach addresses three major challenges in personalized cancer therapy: synergistic drug combination predictions (validated in vitro and in vivo in a genetically engineered murine cancer model), identification of unifying therapeutic targets to overcome intra-tumor heterogeneity (validated in vivo in a human cancer xenograft), and mitigation of cancer cell resistance and rewiring mechanisms (validated in vitro in a human and canine cancer model). Conclusions: These proof-of-concept studies support the use of an integrative functional approach to personalized combination therapy prediction for the population of high-risk cancer patients lacking viable clinical options and without actionable DNA sequencing-based therapy. | |
dc.identifier.citation | Berlow, N.E., Rikhi, R., Geltzeiler, M., Abraham, J., Svalina, M.N., Davis, L.E., Wise, E., Mancini, M., Noujaim, J., Mansoor, A., Quist, M.J., Matlock, K.L., Goros, M.W., Hernandez, B.S., Doung, Y.C., Thway, K., Tsukahara, T., Nishio, J., Huang, E.T., . . . Keller, C.. 2019. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer, 19(1). https://doi.org/10.1186/s12885-019-5681-6 | |
dc.identifier.uri | https://doi.org/10.1186/s12885-019-5681-6 | |
dc.identifier.uri | https://hdl.handle.net/2346/94965 | |
dc.language.iso | eng | |
dc.subject | Artificial intelligence and machine learning | |
dc.subject | Combination therapy | |
dc.subject | Computational modeling | |
dc.subject | Drug screening | |
dc.subject | High-throughput sequencing | |
dc.subject | Pediatric cancer | |
dc.subject | Personalized therapy | |
dc.subject | Sarcoma | |
dc.title | Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Main article with TTU Libraries cover page.pdf
- Size:
- 7.29 MB
- Format:
- Adobe Portable Document Format